NKARTA INC (NKTX)
Health Care · NASDAQ
Clinical-stage biotech pioneering allogeneic, off-the-shelf CAR NK cell therapies for autoimmune diseases and cancers.
What NKARTA INC does
Nkarta is a clinical-stage biopharmaceutical company developing allogeneic (off-the-shelf) engineered natural killer (NK) cell therapies. The company's lead product, NKX019, is a CAR NK cell candidate targeting CD19 antigen for autoimmune diseases including lupus nephritis, systemic sclerosis, myositis, and ANCA-associated vasculitis, currently in Phase 1 trials. Nkarta's platform leverages proprietary technologies to generate abundant NK cells, enhance antigen recognition, and improve cell fitness for scaled, accessible manufacturing and administration.
Themes: ["CAR NK cell therapy","Allogeneic cell therapy","Autoimmune disease treatment","B-cell-targeted immunotherapy","Off-the-shelf cell therapy","Engineered natural killer cells"]
Fundamentals
- Price$3.21 as of 2026-07-09 close
- Market cap$240M as of 2026-07-10
- 1-year return+106.2% as of 2026-07-09 close
- Net margin-17566.7% as of 2026-07-10
- ROE-30.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.89 as of 2026-07-10
Key risks (from latest filing)
["Company is pre-revenue, clinical-stage with no approved products; NKX019 is only in Phase 1 trials with uncertain regulatory and clinical outcomes.","Requires substantial additional capital; dilution to stockholders is likely given significant ongoing losses and no near-term path to profitability.","CAR NK cell approach is novel with unproven manufacturability at scale and unknown long-term safety and efficacy compared to established therapies like CAR T cells."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.